May 06, 2025
BSE Limited
Floor 25, P. J. Towers
Dalal Street, Fort
Mumbai - 400 001
Scrip Code: 530019
National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex, Bandra (E)
Mumbai - 400 051
Symbol: JUBLPHARMA
Sub: Credit Rating
Ref.: Intimation under Regulation 30 of the Securities and Exchange Board of India
(Listing Obligations and Disclosure Requirements) Regulations, 2015
Dear Sirs,
In accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015, we wish to inform you that India Ratings and Research Private Limited has
affirmed Long-term issuer rating of ‘IND AA+’ Rating for Jubilant Pharmova Limited with
a stable outlook. The ratings reflect JPM group’s healthy financial performance during
FY24-9MFY25, primarily led by an improvement in CDMO Sterile Injectables and Generics business.
The instrument-wise ratings are given below:
| Sr. No. |
Rating For |
Amount (Rs. Crore) |
Credit Rating |
Rating Action |
| 1 |
Fund-based Working Capital limits |
150.00 |
IND AA+/Stable/IND A1+ |
Affirmed |
| 2 |
Non-fund-based Working Capital limits |
150.00 |
IND A1+ |
Affirmed |
| 3 |
Term loan |
200.00 |
IND AA+/Stable |
Affirmed |
| 4 |
Commercial paper* |
50.00 |
IND A1+ |
Assigned |
*Commercial paper yet to be issued
The Company has received the rating letter from India Ratings and Research Private Limited on
May 06, 2025 at 12:48 pm.
This is for your kind information and record.
Thanking you,
Yours faithfully,
For Jubilant Pharmova Limited
Naresh Kapoor
Company Secretary